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BACKGROUND: Failure to diagnose and adequately classify 
newly-diagnosed hypertensive patients may lead to non-recognition 
of White Coat Hypertension (WCH) and inappropriate use of anti-
hypertensive medications. This study determined the prevalence 
and predictors of white coat hypertension among newly-diagnosed 
hypertensive patients in a tertiary health centre in Nigeria.  
METHODS: One hundred and twenty newly-diagnosed 
hypertensive patients and 120 controls were recruited for the study. 
All the participants had 24-hour Ambulatory Blood Pressure 
Monitoring (ABPM) using an oscillometric device (CONTEC®). 
Data were analyzed using SPSS version 20.0.  
RESULTS: Out of 120 patients, 52 were males and the mean age 
was 44.2 ± 9.7 years whereas of the 120 controls, 53 were males 
and the mean age was 44.0 ± 7.5 years. The mean body mass index 
of the patients, BMI (27.0 ± 4.5kg/m²) was higher than control 
(24.1 ± 4.5kg/m²), p-value <0.001. The prevalence of WCH was 
36.7%. The mean age and BMI of those with WCH were 43.3 ± 
11.4 years and 26.4 ± 4.5kg/m2 respectively. Females constituted a 
greater proportion (70.5%). In multivariate analysis, high level of 
education and being overweight or obese were significant 
determinants of WCH.  
CONCLUSION: High prevalence of WCH existed among 
participants studied. High level of education and being obese were 
predictors of white coat hypertension. Hence, ambulatory blood 
pressure monitoring should be included as part of routine work-up 
for newly-diagnosed hypertensive patients in order to limit the 
number of those who may be committed to lifelong 
antihypertensive medications with its unwanted side effects. 
KEYWORDS: Prevalence, white coat hypertension, ambulatory 




Systemic hypertension (SH) is a global public health problem and a 
leading cause of death worldwide (1). It is known to run a rapid 
course in Blacks (2). Its diagnosis is usually made using the office
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blood pressure measurement. However, there are 
limitations to its use (3). Studies have shown that 24-
hour Ambulatory Blood Pressure Measurements 
(ABPM) is a stronger predictor of all-cause and 
cardiovascular mortality than office BP measurement 
(4-6), 24-hour ABPM provides automated Blood 
Pressure (BP) measurements during a 24-hour period 
while subjects are engaged in their usual activities, 
including sleep without the doctor’s influence. If 
used for all newly diagnosed hypertensive patients, it 
will aid in identifying BP phenotypes such as White 
Coat Hypertension (WCH) and masked hypertension 
(4, 5). Consequently, fewer drug treatments will be 
necessary, and there will be reduction in the risk of 
adverse drugs reaction that may result from 
unnecessary pharmacologic treatment of WCH (7). 
The use of ABPM is still relatively uncommon 
in Nigeria (8). Hence, limited data exist on the 
prevalence and predictors of WCH in the Country. 
However, a recent meta-analysis in African 
populations revealed that WCH is frequent; hence, 
the need for out-of-clinic BP measurement in the 
diagnosis and management of patients with 
hypertension in Africa (9). Additionally, it has been 
reported that the prevalence of white coat 
hypertension can vary from 12% to 60% depending 
on patients’ selection (10). 
This study, therefore, determined the prevalence 
of WCH and the predictors of WCH among newly-
diagnosed hypertensive patients in a tertiary health 
Centre in Nigeria. 
 
MATERIALS AND METHODS   
Study design and area: The study was a cross-
sectional survey conducted in North Central Nigeria.  
Inclusion criteria: The Patients were drug naïve 
newly-diagnosed hypertensive while the controls 
were apparently healthy sex and age-matched adults 
with normal blood pressure (BP <140/90mmHg). 
Exclusion criteria: Pregnant women, those with 
other cardiovascular diseases and co-morbidities 
were excluded from both study groups.  
Study protocol: The study population consisted of 
240 individuals that included 120 patients with 
newly-diagnosed systemic hypertension and 120 
control participants, seen at the Medical Outpatient 
Departments at the University of Ilorin Teaching 
Hospital.  All eligible participants were informed 
about the study, and informed consent was obtained. 
Thereafter, each participant completed a self-
administered questionnaire. Participants’ 
confidentiality was maintained by using codes 
instead of names and keeping the data away from 
non-members of the research team.  
Sample size calculation/sampling technique: The 
sample size was calculated using the formula for 
cross-sectional survey (11) using prevalence of 
systemic hypertension of 19.3% in Sub-Saharan 
African (12), 95% confidence interval, degree of 
accuracy of 0.05 and attrition rate of 10% to give a 
minimum sample size of 236. For population less 
than 10,000, a correction factor, Nf = n/1+ (n/N) was 
used to determine the final sample size, where n is 
the calculated sample size, N is the total number of 
newly-diagnosed patients seen at the Out-Patient 
Department in one year (N= 144). Therefore, Nf = 
236/2.63888, Nf = 89. Giving the attrition risk of 
20%, the sample size was increased to include 120 
patients and 120 controls. Hence, 120 patients and 
120 control participants were recruited. The sampling 
technique used was consecutive, in which every 
participant that met the inclusion criteria was 
selected. 
Ethical approval: Ethical approval was obtained 
from the Ethical Review Committee of the University 
of Ilorin Teaching Hospital (UITH), Ilorin, before the 
commencement of the study.  
Statistical analysis: Statistical analysis was done 
with SPSS version 20.0. The results were expressed 
in tables with percentages. Quantitative and 
qualitative demographic characteristics were 
summarized and presented in tabular forms. Data 
were expressed as mean ± standard deviation (SD) 
while frequencies were expressed as percentages. The 
Student t-test was used to compare the means of 
continuous variables between two groups that were 
normally distributed while analysis of variance was 
used to compare the means of normally distributed 
continuous variables that were more than two groups. 
Chi-square was used to compare proportions. 
Multivariate analysis was examined by logistic 
regression for the predictors of WCH. The results 
were presented as the odds ratio with corresponding 
95% confidence interval. For all tests, p-value < 0.05 
was considered statistically significant.  
 
Measurements: The patients were antihypertensive-
naïve adults whose mean (three measurements) BP 
was >140/90mmHg. ABPMs were carried out on all 
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the study participants. ABPM was performed with an 
oscillometric device (CONTEC®), which was 
revalidated regularly against a mercury column 
sphygmomanometer. In the office, after a 5-minute 
rest with the participant seated, the BP measurements 
were taken with a mercury sphygmomanometer using 
an appropriate cuff, taken on the bare arm, which was 
supported and maintained at the heart’s level. The 
mean of 3 measurements was used as the office BP. 
Thereafter, ABPM was fixed on each participant with 
measurements taken every 30 minutes from 7a.m. to 
9.59 p.m. and every 1 hour from 10:00 p.m. to 6.59 
am while the participant maintained his/her usual 
activities throughout the day. The appropriate cuff for 
the arm’s circumference was placed on the non-
dominant arm, and the participants were instructed to 
maintain their arm stretched out at the heart level and 
be still during automatic BP measurements. Using the 
European Society of Hypertension (ESH) guidelines 
for the management of hypertension’s cut-off limits; 
Normal day-time and mean 24-hour ABPM were 
135/85mmHg and 130/80mmHg respectively, but 
night-time ABPM was placed at 120/80mmHg (3). 
Participants were divided into subgroups based 
on the office BP and ABPM: 
A. Individuals who were hypertensive by both 
methods were referred to as those with true or 
sustained systemic hypertension. 
B. Individuals who were hypertensive by clinic 
measurement and normotensive by ambulatory 
measurement were referred to as those with white 
coat hypertension (WCH).   
C. Individuals who were normotensive by both 
methods were referred to as truly normotensive 
individuals.  
D. Individuals who were normotensive by clinic 
measurement and hypertensive by ambulatory 
measurement were referred to as those with masked 
hypertension (MH).   
WCH is defined as office BP >140/90mmHg but 
normal day-time ambulatory BP <135/85mmHg. The 
Statistical Software for Social Sciences (SPSS 20) 




The demographic, anthropometric and clinical 
parameters of the study participants: A total of 
240 participants consisting of 120 patients and 120 
healthy controls were studied. The demographic, 
clinical and anthropometric parameters of the study 
participants are presented in Table 1. 
 
TABLE 1. The demographic, anthropometric and clinical parameters of the study participants 
 
VARIABLES HYPERTENSIVE 
MEAN±SD /n (%) 
CONTROL 
MEAN±SD/n (%)  
      ρ-value 
Male n (%) 52(43.3) 53(44.2)      0.897 
Female n (%) 68(56.7) 67(55.8)      0.897 
Age (years)                    44.2 ± 9.7                                            44.0±7.5      0.403 
Weight (kg)                75.0 ±12.4                                          67.1±12.3      <  0.001* 
Height (m)                   1.67±0.08                                        1.67±0.10                     0.356 
BMI(kg/m²)   27.0 ± 4.5  24.1 ± 4.2   < 0.001* 
WC (cm)                   90.2 ± 13.1 82.7 ± 11.8   < 0.001* 
HC (cm)                   101.2 ± 11.8 96.2 ± 9.8   < 0.001* 
Waist-Hip Ratio                            0.89 ± 0.09 0.86 ± 0.06      0.101 
Pulse Rate(bpm) 80.5 ± 13.2 75.3 ± 11.8       0.468 
Office SBP (mmHg)                                      153.4 ± 16.9 116.8 ± 10.9   < 0.001* 
Office DBP (mmHg)                                                                             96.2 ± 12.1                                           71.9 ± 8.9   < 0.001* 
Family history of SH (%) 82(68.3%) 51(42.5%)   < 0.001* 
Smoking n (%)                                          5(4.2%)                                                           3(2.5%)      0.474 
Alcohol consumption (%)                                         7(5.8%)                                           5(4.2%)      0.556 
Key: *= Statistically significant, SD = Standard deviation, BMI = Body mass index, WC = Waist circumference, HC = Hip 
circumference, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, SH =Systemic hypertension, bpm = beats per 
minute 
The mean weight and waist circumference of the 
patients (75.0 ± 12.4kg and 90.2 ± 13.1cm) were 
higher than the mean weight and waist 
circumference of the control participants (67.1 ± 
12.3kg and 82.7 ± 11.8cm); p-values <0.001 and 
<0.001 respectively. The mean BMI of the 
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patients (27.0 ± 4.5g/m²) was greater than the 
control participants (24.1 ± 4.5kg/m²), p-value 
<0.001.  In the hypertensive group, 68.3% had 
positive family history of SH compared with 
42.5% in the control group; p-value < 0.001. 
However, the mean office SBP and DBP in 
patients (153.4 ± 16.9mmHg and 96.2 ± 
12.1mmHg) respectively were significantly higher 
than the mean office SBP and DBP in the control 
group (116.8 ± 11.0 and 71.9 ± 8.9mmHg); p-
values < 0.001 and <0.001 respectively. 
Prevalence and characteristics of White Coat 
Hypertension: Among the patients’ group, the 
prevalence of white coat hypertension (WCH) was 
36.7% as shown in Figure 1. Systemic 
hypertension (SH), WCH and truly normotensive 
groups were classified as groups A, B and C 
respectively.   
As illustrated in Table 2, a greater proportion 
of those with WCH were females (70.5%). 
Compared with group A (44.7± 8.8 years) and 
group C (42.4 ± 7.7 years); p-value = 0.222. Also, 
there is no significant difference in the BMI of 
WCH group (26.4 ± 4.5kg/m2) compared with 
group A (27.5± 4.3kg/m2) and group C (24.0 ± 4.2 
kg/m2). However, the BMI of group A was 




Figure 1: The Prevalence of white coat hypertension among patients with newly-diagnosed SH 
 
The office and ambulatory blood pressure 
indices of the WCH in comparison with SH and 
truly normotensive group: The clinical 
parameters of participants in the three groups are 
shown in Table 2. The office SBP and DBP in the 
WCH group (144.2±12.2 and 88.3 ± 10.3 mmHg) 
were intermediate between groups A 
(158.0±17.7mmHg and 100.2±11.4mmHg) and C 
(117.0±11.7mmHg and 72.3 ± 9.6mmHg) 
respectively: p-values <0.001and <0.001. The 
ambulatory day-time SBP and DBP in the WCH 
group (124.5±6.0 and 74.5±5.3mmHg) were 
intermediate between groups A (145.4±11.5 and 
91.3±9.7mmHg) and group C (116.2±8.7mmHg 
and 69.4±7.2mmHg): p-values <0.001and <0.001 
respectively.  Similarly, the ambulatory night-time 
SBP and DBP in the WCH group (118.6±8.5 and 
69.2±5.7mmHg) were intermediate between 
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groups A (140.0±16.0 and 84.2±10.7mmHg) and 
group C (108.8±9.2 and 61.8±7.6mmHg): p-values 
<0.001and <0.001 respectively.   
 
Table 2: The anthropometric and ambulatory parameters of the participants with true SH, WCH and normal 
blood pressure 
 
VARIABLES TRUE SH  (A) 
MEAN±SD 







Age (years)                    44.7±8.8 43.3±11.4                                           42.41±7.7    0.222 
BMI(kg/m²)   27.5±4.3 26.4±4.5 24.0±4.2 < 0.001 π ©     
WC (cm)                   91.8±11.3 87.3±15.4 82.5±11.9 < 0.001 π      
Office SBP 158.0±17.7 144.2±12.2 117.0±11.7 < 0.001 Ω π ¥           
Office DBP 100.2±11.4 88.3±10.3 72.3±9.6 < 0.001 Ω π ¥                
Ambulatory daytime 
SBP 
145.7±11.5 124.5±6.0 116.2±8.7 < 0.001 Ω π ¥                
Ambulatory daytime 
DBP                                   
91.3±9.7 74.5±5.3 69.4±7.2 < 0.001 Ω π¥         
Ambulatory 
nighttime SBP 
140.0±16.0 118.6.0±8.5 108.8±9.2 < 0.001 Ω π ¥           
Ambulatory 
nighttime DBP 
84.2±10.5 69.2±5.7 61.8±7.6 < 0.001 Ω π ¥           
Ambulatory daytime 
pulse rate 
85.8±10.7 79.4±9.2 78.5±9.6 < 0.001 Ω π ¥  
Ambulatory daytime 
pulse pressure 
53.8±8.7 50.3±6.5 46.7±6.1 < 0.001 Ω π ¥                
 
Key: Ω , A statistically greater than B; π, A statistically greater than C; ¥, B statistically greater than C; ©, B statistically greater 
than A;µ, C statistically greater than A; €, C statistically greater than B; WCH, White coat hypertension; SH, Systemic 
hypertension; SD, Standard deviation; BMI, Body mass index; WC, Waist circumference; HC, Hip circumference; SBP, Systolic 
blood pressure; DBP, Diastolic blood pressure 
 
Predictors of WCH: Multivariate analysis 
showed that high level of education [odds ratio 
(OR) 12.378, 95% confidence interval (CI) 2.167-
70.709, p = 0.005] and being overweight/obese 
(OR 0.227, 95% confidence interval (CI) 0.056 - 
0.920, p = 0.038) were predictors of white coat 
hypertension as shown in Table 3. WCH was not 
significantly associated with age, sex, and family 
history of hypertension. 
 
Table 3: Predictors of White Coat Hypertension 
 
Predictor variable Categories of variable         OR CI (95%)  ρ-value 
Age - 1.009 0.952-1.071 0.755 
Sex  1.621 0.503-5.228 0.418 
Level of education Others (ref.) 12.378 2.167-70.709 0.005 
Family history of 
hypertension 
 0.787 0.260-2.383 0.672 
Overweight/obese Normal (ref.) 0.227 0.056-0.920 0.038 




This study has demonstrated the usefulness of 
ABPM for proper diagnosis and classification of 
patients. ABPM has enabled the diagnosis of a 
potentially enigmatic SH subtype such as white 
coat hypertension (13). The prevalence of WCH in 
this study is 36.7%. This is higher than 14.1% that 
was previously reported in a Nigerian population 
by Isiguzo et al. (8). Perhaps, the duration of 
hypertension may be a differential factor between 
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both studies, patients with newly diagnosed 
hypertension being more prone to the white-coat 
effect than patients with long-standing 
hypertension. Also, in this study, office BP were 
taken manually using the standard mercury 
sphygmomanometer rather than the automated 
sphygmomanometer used by Isiguzo et al. This 
could also account for lower prevalence of WCH 
in their study because automated oscillometric BP 
sphygmomanometer has been shown to give lower 
BP values (14). Takah et al. reported 25% among 
Cameroonians (15) whereas Abir-Khalil et al. 
reported 33% as the prevalence of WCH in 
Morocco, North Africa (16). However, the 
prevalence in our study falls within the range of 
24% to 39% that was reported by Fagard et al (17) 
in a European study population. Verdecchia et al. 
reported that depending also on the selection of 
patients and groups of patients, the prevalence of 
white coat hypertension can vary from 12% to 
60% (10). 
Understanding the likely profile of 
individuals with WCH will facilitate the selection 
of patients for ABPM. In this study, higher level 
of education and being overweight or obese were 
significant predictors of white coat hypertension. 
People with higher level of education are more 
likely to be gainfully employed and financially 
buoyant to eat more which predispose to the 
likelihood of being overweight or obese. 
Additionally, obese patients usually have higher 
office BP; hence, they exhibit larger clinic-awake 
differences compared with their non-obese 
counterparts. Studies of the association between 
BMI and ABPM variables have shown conflicting 
findings. Takah et al. found BMI to be the only 
determinant of WCH (15), whereas Ben-Dov et al. 
found no association between BMI and WCH in a 
large retrospective study of patients referred for 
ABPM (18). Worth mentioning is the fact that 
female gender, age and family history of 
hypertension were not associated with WCH in 
this study. This concurred with findings by Takah 
et al. in Cameroon which also showed that age, 
sex, and family history of hypertension were not 
associated with WCH in their study population 
(13). However, on the contrary, some studies have 
shown that female gender, age, and family history 
of hypertension were determinants of WCH (19-
21). Accounting for the conflicting findings in the 
predictors could be differences in the study 
population. Most previous studies were carried out 
in different parts of the world other than the 
Nigerian population. Hence, there is a need to 
carry out more future studies on the predictors of 
WCH in our study population. 
Although individuals with WCH might not 
require pharmacotherapy immediately, there is a 
need to follow them up regularly for early 
detection of incident true hypertension and also 
encourage them to adopt non-pharmacologic 
strategies such as lifestyle modification. This is 
strengthened by findings from a prospective study 
by Verdecchia et al which showed that 37% of 
their WCH patients spontaneously developed 
incident true SH during a follow-up that ranged 
from 6 months to 6 years (22). 
The recognition of WCH is important for 
treatment initiation, as this sub-group will only 
require lifestyle modification and follow-up, rather 
than pharmacotherapy (7). Aside the hypotension-
related complications that could arise from 
unnecessary pharmacotherapy of individuals with 
WCH, it is also waste of resources especially in a 
country where the majority of the population 
spend ‘out of pocket’ for healthcare (23).  
Therefore, identification of this BP phenotype 
would result in a net reduction in the cost of 
managing SH, thereby guaranteeing judicious and 
efficient utilization of healthcare resources and 
improved population health outcome.  
This study, unlike the previous one in 
Nigeria, also examined predictors of WCH. The 
study is cross-sectional; therefore, causal inference 
cannot be drawn. It is limited to one tertiary 
hospital in Nigeria. Hence, a multi-centre study 
will be necessary. 
There was a high prevalence of WCH among 
the studied participants. High level of education 
and being overweight or obese were significant 
determinants of white coat hypertension. Hence, 
there is a need to include ABPM as part of routine 
work-up for newly-diagnosed hypertensives who 
are highly educated and obese in order to limit the 
number of those who may be committed to 
lifelong antihypertensive medications with its 
unwanted side effects. 
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